Strides Pharma Science Ltd Share Price Today - Strides Pharma Science Ltd Stock Price Live NSE/BSE

Strides Pharma Science Ltd

NSE: STAR BSE: 532531

₹893.95

(2.41%)

Thu, 12 Mar 2026, 05:05 am

MTF 5xInvest in Strides Pharma Science Ltd with 5x Leverage Buy with MTF

Market Cap80.39B

PE Ratio16.11

Dividend0.46

Health Technology

Pharmaceuticals: Major

24.5K

Strides Pharma Science Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
8230.56
Net Profit
3597.51
P/B
2.42
Sector P/E
32.85
P/E
1.72
EV/EBITDA
1.92
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
10.03
ROCE (Industry)
12.82
RONW (Industry)
12.23
ROE
150.84
ROCE
14.28
Debt/Equity
0.94
EPS (TTM)
59.78
Dividend Yield
0.45
Book Value
298.99
Interest Cover
2.67

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (2.7x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (9.1x coverage).
Cash flow for Strides Pharma Science is expected to increase by more than 50% in 2 years time.
Strides Pharma Science's earnings are expected to grow significantly at over 20% yearly.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Strides Pharma Science's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Strides Pharma Science's dividend is below the markets top 25% of dividend payers in India (3.08%).
Strides Pharma Science is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	27.86	27.86	28.30	28.30	26.82
FII	29.52	28.51	28.02	28.32	28.48
DII	13.02	12.98	13.30	13.72	16.92
Public	29.59	30.64	30.37	29.65	27.77
Government	0.01	0.01	0.01	0.01	0.01

Technical Analysis

RSI

59.96

MACD

2.12

50 DMA

876.97

200 DMA

872.14

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1086.85	969.85	910.70	852.85	793.70	735.85	618.85
Fibonacci	969.85	925.16	897.54	852.85	808.16	780.54	735.85
Camarilla	883.72	873	862.27	852.85	840.82	830.10	819.38

Pivots Level: Classic

+234.00

1086.85

+117

969.85

+57.85

910.70

852.85

Pivot Point

LTP: 897.55

-59.15

793.70

-117

735.85

-234

618.85

Moving Average

SMAEMA

Period

Value

10-EMA
872.41
20-EMA
868.41
30-EMA
869.31
50-EMA
873.24
100-EMA
873.37
200-EMA
842.80

Announcement Date	Purpose	Action	Ex Date
30 Jan 2026	board-meetings	Quarterly Results
31 Oct 2025	board-meetings	Quarterly Results
09 Jul 2025	agm
22 Jun 2025	dividend	Final Dividend - Rs. - 4	22 Jul 2025
22 May 2025	dividend	₹4.00 Dividend /Share	22 Jul 2025
05 Sept 2024	agm
09 Aug 2024	dividend	Final Dividend - Rs. - 2.5	09 Sept 2024
08 Aug 2024	egm
22 May 2024	dividend	₹2.50 Dividend /Share	09 Sept 2024
25 Sept 2023	merger-demergers	Strides Pharma Science Ltd Demerger	06 Dec 2024

Strides Pharma Science Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Cipla Ltd

Strides Pharma Science Ltd About

Strides Pharma Science into the development and manufacture of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1990

Headquarters

CEO

Arun Kumar

Employees

Contact

Website

http://www.strides.com

investors@strides.com

Phone

91-22-27892924/27893199

Location

No 201 Devavrata Sector 17, Vashi, Navi Mumbai, Maharashtra, 400703

Year	History
2020	Strides Pharma Science receives USFDA approval for Prednisone tablets. Strides Pharma Science receives USFDA approval for generic anti-bacterial capsules. Strides arm receives EIR for US facility.
2021	Stelis Biopharma commissions greenfield vaccine manufacturing facility at Bengaluru. Strides and TLC partner to launch black fungus drug in India. Strides Pharma arm receives USFDA approval for potassium chloride oral solution. Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
2022	Strides receives USFDA approval for Potassium Chloride Oral Solution. Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules. Strides receives USFDA approval for Cyclosporine Softgel Capsules. Strides receives USFDA approval for Ibuprofen Oral Suspension. Strides partners with Medicines Patent Pool to commercialize generic Pfizer COVID-19 Oral Treatment across 95 markets.
2023	Strides receives USFDA approval for Generic Suprep Bowel Prep Kit. Strides receives USFDA approval for Levetiracetam Oral Solution. Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumarate tablets. Strides receives USFDA approval for Icosapent Ethyl Capsules. Strides receives tentative USFDA approval for Dolutegravir tablets.
2024	Strides receives USFDA approval for Fluoxetine Tablets 60 mg. Strides Pharma unit receives USFDA approval for generic drug to treat gastrointestinal diseases. Strides receives USFDA approval for Theophylline Extended-Release Tablets 300 mg and 450 mg. Strides acquires balance stake in Strides Global Consumer Healthcare Limited, UK. Strides receives USFDA approval for Sucralfate Oral Suspension 1gm/10 mL. Strides receives USFDA approval for Sevelamer Carbonate Tablets 800 mg. Strides receives USFDA approval for Fluoxetine Tablets 10 mg and 20 mg.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Sell	578738	938.69	31 Oct 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	578738	937.22	31 Oct 2025
AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	Buy	518350	558.88	22 Jan 2025
AMANSA HOLDING PRIVATE LTD.	Buy	1140301	713	09 Feb 2024
BAJAJ FINANCE LIMITED	Sell	804629	713	09 Feb 2024
AMANSA HOLDING PRIVATE LTD.	Buy	594000	659.41	02 Jan 2024
AMANSA HOLDING PRIVATE LTD.	Buy	1223200	659.81	02 Jan 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	575276	546	11 Dec 2023
GRAVITON RESEARCH CAPITAL LLP	Buy	575276	546.26	11 Dec 2023
BNP PARIBAS ARBITRAGE	Buy	949000	470	06 Nov 2023

Strides Pharma Science Ltd News

Strides Pharma Completes Neviton Acquisition

Strides Pharma's subsidiary Arco Lab acquired remaining 50% stake in Neviton Softech for Euro 2 million, making it a wholly owned subsidiary effective February 16, 2026.

18 Feb 2026

co actions results

Strides Gets USFDA Closure for NY Facility Inspection

Strides Pharma Inc receives USFDA closure report (EIR) for Chestnut Ridge facility with VAI classification. Inspection covered nasal sprays domain and drug-device combinations.

05 Feb 2026

stocks

Strides Pharma Q3 Net Profit Surges 127% YoY

Strides Pharma Science reports consolidated net profit of ₹2 billion in Q3, marking a significant 127% increase from ₹880 million in the same quarter last year.

30 Jan 2026

co actions results

Strides Pharma Gets FDA Form 483 with 4 Observations

Strides Pharma Science completes US-FDA inspection at its USA facility. FDA issues Form 483 with four procedural observations following the regulatory review.

26 Dec 2025

stocks

Strides Pharma Gets 4 FDA Observations, Q2 Profit Jumps 82%

Strides Pharma Science received 4 procedural FDA observations at NY facility with no supply impact expected. Q2 net profit surged 82% to ₹131.50 crore with revenue up 4.6% to ₹1,221 crore.

24 Dec 2025

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800